BERLIN, Germany, Aug. 02, 2005 (PRIMEZONE) -- Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, today announced that, following a distinguished career, Gary Schweikhardt, co-founder and CEO of the company's US subsidiary, Epigenomics, Inc., based in Seattle, will retire at the end of 2005 due to personal reasons. Mr Schweikhardt will continue to be an advisor to Epigenomics.
END OF AD HOC
"It is with great regret that we have accepted Gary's retirement and would like to thank him for his dedication to Epigenomics over the past five years. His commitment to DNA methylation research and its application to cancer diagnostics has been an inspiration to everyone who has worked with him. He has also been a great mentor and sounding board for me personally," noted Alex Olek, CEO of Epigenomics. "We wish him much happiness in his retirement."
"I have truly enjoyed working at Epigenomics and with a team of individuals commited to improving people's lives," stated Gary Schweikhardt. "The products under development with the company could potentially have a great impact on the way that diseases such as cancer are diagnosed and ultimately treated. I am extremely pleased to have played a role in this new area of medical innovation and will closely follow Epigenomics' further development."
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. By detecting and interpreting DNA methylation patterns, Epigenomics' tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics collaborates with Roche Diagnostics on the development of several diagnostic products in cancer. The company has its headquarters in Berlin, Germany, and a wholly owned subsidiary in Seattle, USA. For more information, please visit our website at www.epigenomics.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.